logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

LIVZON PHARMA (01513) spent 8.7832 million yuan on September 24 to repurchase 250,000 shares of A shares.

date
18:35 24/09/2024
avatar
GMT Eight
Lizhu Pharmaceutical (01513) announced that the company invested 8.7832 million yuan on September 24, 2024...
LIVZON PHARMA (01513) announced that the company spent 8.7832 million yuan to repurchase 250,000 A shares on September 24, 2024. The repurchase price was between 34.95 yuan and 35.76 yuan per share.
Related Articles
Under Musk's ownership, SpaceX is aiming to conduct the largest IPO in history, with plans to raise up to $75 billion.
US Stock Market Move | Popular Chinese concept stocks continue to rise, JD.com, Inc. Sponsored ADR Class A (JD.US) up more than 7%
HK Stock
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
Under Musk's ownership, SpaceX is aiming to conduct the largest IPO in history, with plans to raise up to $75 billion.
US Stock Market Move | Popular Chinese concept stocks continue to rise, JD.com, Inc. Sponsored ADR Class A (JD.US) up more than 7%
KAISA HEALTH (00876) released its annual performance with a net loss attributable to shareholders of HK$46.678 million, a 0.7% increase year-on-year.
HK Stock
RECOMMEND
“Lobster” Contained: Why The Financial Sector Is Reluctant To Adopt It
“Lobster” Contained: Why The Financial Sector Is Reluctant To Adopt It
icon
25/03/2026
Hong Kong AI New Narrative: Embracing Token Economics
Hong Kong AI New Narrative: Embracing Token Economics
icon
25/03/2026
Is The Spring For Pharma Stocks Here? WuXi AppTec Rises Over 9% As Institutions Back An Industry Inflection
Is The Spring For Pharma Stocks Here? WuXi AppTec Rises Over 9% As Institutions Back An Industry Inflection
icon
25/03/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.